Both HL and depression are independent risk factors for eventual conversion to dementia. 2 key findings →
Design: longitudinal study Participants: 8,529 Evidence: moderate
Full summary, score breakdown and related studies → Original source
34,580 published Alzheimer's and dementia studies, each summarized in plain English, scored out of 100 and linked to the original paper.
Both HL and depression are independent risk factors for eventual conversion to dementia. 2 key findings →
Design: longitudinal study Participants: 8,529 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Of 1,164 participants (mean age 73.5 years, 64% women), 580 (49.8%) had mild hearing impairment and 196 (16.8%) had moderate/severe hearing impairment. 5 key findings →
Design: longitudinal study Participants: 1,164 Evidence: moderate
Full summary, score breakdown and related studies → Original source
A relationship between SCHL and cognitive decline was observed for the Letter Fluency test. 4 key findings →
Design: longitudinal study Participants: 263 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Over 68,904 person-years of follow-up, 1,349 participants developed dementia. 5 key findings →
Design: longitudinal study Participants: 1,349 Evidence: moderate
Full summary, score breakdown and related studies → Original source
The mean age was 58.4 years (SD = 6.2). A 20-dB (equivalent to a one-category worsening) increase in HL was associated with a -1.53 (95% CI, -2.11, -0.94) raw score point difference in the DSST, adjusting for demographics, hearing aid use, and cardiovascular disease. 4 key findings →
Design: cross-sectional Participants: 5,277 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Forkhead Box O 3 (FOXO3) genotype is strongly associated with human longevity and may be protective against neurodegeneration. 3 key findings →
Design: prospective cohort Evidence: moderate
Full summary, score breakdown and related studies → Original source
Long follow-up of a general aged population explains several inconsistencies of earlier reports. 3 key findings →
Participants: 650 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Our study suggests that slow gait precedes cognitive decline. 5 key findings →
Participants: 1,478 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
PM2.5 may contribute to racial/ethnic disparities in AD risk and its associated increase in AD risk was stronger among Black women. 2 key findings →
Participants: 481 Evidence: moderate
Full summary, score breakdown and related studies → Original source
HI in older adults is associated with increased mortality, independent of demographics and cardiovascular risk factors. 5 key findings →
Participants: 1,958 Evidence: low
Full summary, score breakdown and related studies → Original source
During a median 11.7 years follow-up, 5 905 incident cases of all-cause dementia were identified. 5 key findings →
Participants: 459 Evidence: low
Full summary, score breakdown and related studies → Original source
Our study confirms the strong link between hearing status and the risk of disability, dementia, and depression. 4 key findings →
Participants: 3,777 Evidence: low
Full summary, score breakdown and related studies → Original source
Poor vision is associated with the development of CIND. 5 key findings →
Participants: 351 Evidence: low
Full summary, score breakdown and related studies → Original source
Both decreased general cognition and decreased processing speed appear to be potential risk factors for serious falls in the elderly. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 34,580 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 34,580 records, built mostly from automated pulls of Europe PMC (68.8% of the library) and OpenAlex (14.7%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,050 records (3% of the library) are not peer-reviewed — 966 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →
Newest studies, as a dated timeline → Atom feed Where this research is being discussed: events
Last updated